Alicaforsen

Phase 3RNA therapy

Ionis Pharmaceuticals

Alicaforsen is one of 50 small molecule programs targeting Ulcerative Colitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative ColitisActive, not recruiting

PouchitisActive, not recruiting

Ulcerative ColitisPhase 2

Active, not recruiting

PouchitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Phase 3

1 2

Mounjaro

Eli Lilly

Phase 3

1 3

Pulmicort

SSalix

Phase 3

3 4

Adtralza

LEO Pharma

Phase 3

1 5

Purinethol

SStason

Phase 3

1 6

ABX464

AAbivax S.A.

Phase 3

8 7

TA-650

Tanabe Pharma Corporation

Phase 3

1 8

Simponi

Johnson & Johnson

Preclinical

15 9

Alicaforsen

Ionis Pharmaceuticals

Phase 3

2 10

Remicade

OOrganon and Co

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ulcerative Colitis2 trials

ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.

Completed· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Phase 2·NCT00063830

ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis

Completed· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Phase 2·NCT00063414

Crohn's Disease2 trials

Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease

Completed· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Phase 3·NCT00048113·150 enrolled

Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease

Completed· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Phase 3·NCT00048295·150 enrolled

Phase 11 trial

Phase 1 Food Effect Study for Alicaforsen Tablets

Completed·AAtlantic Pharmaceuticals Ltd·Phase 1·NCT03473626·15 enrolled

Pouchitis1 trial

Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics

Completed·AAtlantic Pharmaceuticals Ltd·Phase 3·NCT02525523·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Alicaforsen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alicaforsen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alicaforsen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ionis Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 3[1]
Company: Ionis Pharmaceuticals

Alicaforsen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ulcerative Colitis2 trials

Crohn's Disease2 trials

Phase 11 trial

Pouchitis1 trial

References

Drug Info

Quick Facts

Related News